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The social gradient in health describes a graded 
association between an individual’s position on 
the social hierarchy and health: the lower the 
socioeconomic position of an individual, the worse 
their health.1 The fact that the social gradient extends 
from the highest echelons of society to the lowest 
suggests that everyone is affected to a greater or 
lesser extent by the social determinants of health. 
One component of social cohesion is making 
common cause between people at various points on 
the social ladder. However, people at the extremes 
can appear to be on a different scale to the rest of 
society. F Scott Fitzgerald famously began his story 
The Rich Boy, “Let me tell you about the very rich. 
They are different from you and me”.2 In societies with 
substantial inequality, the considerable gap between 
the top 0·1% of income earners and the rest of society 
threatens social cohesion.
Different, too, are socially excluded populations: the 
homeless, people with substance use disorders, sex 
workers, and prisoners. These individuals can seem 
to be off the scale of the social hierarchy completely, 
which represents a further challenge to social cohesion. 
For example, in the first of two papers on inclusion 
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that would require many years of an antiresorptive 
drug treatment alone.16,17 In a direct comparator trial18 
of romosozumab or alendronate for 1 year, followed by 
alendronate for 2 years more in women with prevalent 
vertebral fractures, the incidence of new vertebral 
fractures was reduced by 37% at 1 year and 48% at 
2 years in participants who received romosozumab 
first, whereas the incidence of clinical and non-
vertebral fractures was significantly reduced in this 
group compared with alendronate alone by the end of 
the analysis (median 33 months). 
Ultimately, these studies should lead clinicians to 
reconsider the most efficient sequence of therapy in 
patients at high risk of fracture: namely, a bone-forming 
drug first, rather than one too late, or not at all.
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health in The Lancet, Robert Aldridge and colleagues3 
found that socially excluded populations have a 
mortality rate that is nearly eight times higher than 
the average for men, and nearly 12 times higher for 
women. By contrast, individuals (aged 15–64 years) 
in the most deprived areas of England and Wales have 
a mortality rate that is 2·8 times higher in men and 
2·1 times higher in women than in individuals in the 
least deprived areas. To adapt Jeremy Bentham’s turn 
of phrase,4 social exclusion is deprivation upon stilts.
To put it less colourfully, the causes of excess morbidity 
and mortality in socially excluded populations (ie, the 
social determinants of health) are not so much different 
from the causes of health inequalities more generally but 
differ in their degree. Multiple intersecting causes and 
multiple forms of morbidity characterise social exclusion. 
The result is people with little hope or prospects and 
considerably shortened lives. The challenge is to bring 
socially excluded populations in from the cold—literally 
and metaphorically—and to provide them with the 
opportunity to be part of a diverse and flourishing 
society. The concerned practitioner might despair at 
achieving such social inclusion.
The second of the two papers on inclusion health in 
The Lancet,by Serena Luchenski and colleagues,5 provides 
evidence to banish despair. The authors report that 
intervention is possible and can make a difference to the 
lives of the four excluded groups included in their Review: 
homeless individuals, prisoners, sex workers, and people 
with substance use disorders. These four populations, of 
course, overlap—eg, substance use disorder is common 
in the other three socially excluded groups.
The methods used in both papers are of high quality. 
But therein lies a problem. As identified by Luchenski 
and coworkers, the effect of basing their work on 
systematic reviews is a focus on proximate interventions 
on individuals—eg, the Review includes many papers 
on pharmacological treatment of substance use 
disorder. These downstream interventions have been 
covered, for the most part, in the scientific literature. There 
has been much less focus on structural interventions. If 
one went purely by the numbers of papers published, 
one would put effort into pharmacological treatment 
and would ignore housing; emphasise case management 
and ignore poverty. Much of the literature included in 
Luchenski and coworkers’ Review was from populations 
with substance use disorders, with few publications about 
homeless people and prisoners, and almost no studies on 
sex workers. For individuals committed to evidence-based 
policies, this poses a dilemma: efforts that promote social 
inclusion have to be encouraged, but the fact that sex 
workers have not been included in systematic reviews, 
and prisoners have only been included rarely, should not 
result in inaction.
The focus on systematic reviews of interventions 
in Luchenski and colleagues’ Review is encouraging 
because it means that much can be done, now and 
relatively quickly, to promote inclusion health. Building 
on the authors’ claim that structural interventions have 
been underemphasised, the causes of the causes should 
also be focused on.
A focus on the health of prisoners shows how a 
societal approach must take different forms. Aldridge 
and colleagues report that prisoners have shockingly 
high all-cause mortality and mortality from injuries 
and poisonings. Part of the reason will not be prison 
itself but the multiple problems that prisoners have. 
For example, prisoner’s involvement in drugs might 
have resulted in their imprisonment. It is also well 
known that exposure to adverse childhood experiences 
increases the risk of substance use disorder, mental 
illness, and violent behaviour—all of which increase 
an individual’s risk of imprisonment.6 But, prison 
might well be the worst place imaginable in which to 
detain young people who are damaged. The public 
need to be protected, of course, which is one reason 
for imprisoning people,7 but by what stretch of the 
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The Lancet–CAMS Health Summit 2018: a call for abstracts  
The Lancet and the Chinese Academy of Medical Sciences 
(CAMS) have held three successful health summits in 
2015–17 in Beijing, China. We continue to support China’s 
health science research communities and invite abstract 
submissions from China for the 2018 The Lancet–CAMS 
Health Summit, to be held on Oct 27–28 in Beijing. 
Submissions are invited from all aspects of health science, 
including, but not limited to: translational medicine; 
clinical medicine; public health; global health; health 
policy; the environment and ecological systems; primary 
care; maternal, newborn, child, and adolescent health, 
health professionalism; and medical education. 
The event will consist of keynote presentations by 
leading researchers from China and beyond, oral and 
poster presentations of selected abstracts, launch of 
The Lancet’s annual China themed issue, and writing and 
publishing sessions with editors. The Lancet will publish 
accepted abstracts online and in a conference booklet. 
Abstracts must be relevant to health science in China.
The conference language will be English. Abstracts 
should be written in English, up to 300 words in length, 
with no references, tables, or figures. Submissions 
should be structured and include the following sections: 
background (including context and aim); methods; 
with disordered behaviour, mental illnesses, or 
multiple morbidities in a place that foments violence, 
promotes drug use, and labels people for life, such 
that their chances of being socially included on release 
are drastically reduced? Deciding whether people are 
damaged by prison or whether they brought all their 
problems with them into prison is not straightforward.
On the assumption that prison does have negative 
effects, then it is of concern that societies have markedly 
different rates at which they imprison individuals. 
In Japan, the prevalence of imprisonment is 48 per 
100 000 individuals compared with 148 per 100 000 in the 
UK and 698 per 100 000 in the USA.8 These differences, in 
part, reflect differences in crime rates; but they also reflect 
variation in the operation of the criminal justice system, in 
policing practices, and the availability of guns.
A welcome feature of the inclusion health approach 
advocated by Luchenski and colleagues5 is user involve-
ment, which aims to enable people to improve their own 
health. We need the involvement of society as a whole 
to tackle the causes of the causes of social exclusion and 
its dramatic health consequences. This approach might 
save money and it is the right thing to do.
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